Cellectis SA AI Stock Analysis
Want to see FR:ALCLS full AI Analyst Report?
Cellectis SA (ALCLS) AI Stock Analysis
Cellectis SA
(Paris:ALCLS)
The score is primarily constrained by severe financial weakness, including recurring losses, balance-sheet erosion, and high cash burn. Weak technical positioning and the negative P/E provide little support, while the promising gene-editing pipeline and extended cash runway offer meaningful but highly speculative upside.
Cellectis SA (ALCLS) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 250.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 455.25K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 0.66
- Revenue Growth
- -5.98%
- EPS Growth
- -8.67%
- Country
- France
- Employees
- 227
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cellectis SA Business Overview & Revenue Model
Company Description
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric...
How the Company Makes Money
Cellectis makes money primarily through (1) collaboration and license-related revenue and (2) to a lesser extent, service/other operating revenue, with limited or no recurring product sales typical of many clinical-stage biotech companies. 1) Collabo...
Cellectis SA Earnings Call Summary
The call was strategically optimistic, centered on the transition to in vivo gene editing and encouraging preclinical results for HEAL-101 and HEAL-201. The company reiterated clinical timelines, described its LNP safety and prior clinical experience favorably, and expects cash runway into the second half of 2028. These positives were offset by the discontinuation of legacy cell therapy programs, planned headcount reductions, a substantial decline in revenue, lower cash and financial assets, and restructuring-related expenses. Overall, the number and strength of the stated pipeline and financing highlights outweighed the challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Cellectis said the investigator-initiated trial for HEAL-101 in China is on track, with preliminary clinical data expected in the second half of 2027; dose escalation is expected to start in Q1, the starting dose is anticipated to be effective, and by the end of year the company expects to start seeing the nine-month type of durability of effect. HEAL-201 is planned to enter phase I, with preliminary clinical data expected in the first half of 2028, while LDL-C reduction data will be provided in June. The company currently expects global headcount to be reduced by up to 70% from its pre-transition level over the course of 2026 and 2027, and expects to have a cash runway into the second half of 2028. Management expects HEAL-101 efficacy to be at least as good as the current treatments, is targeting the number of patients hitting under that target of 500, and estimates the target population at about 1.1 million across U.S. and EU5, or EU4 plus U.K.
Cellectis SA Financial Statement Overview
Summary
Financial performance is severely weak: persistent operating losses, declining equity, elevated leverage, and substantial negative operating and free cash flow outweigh the company’s high gross margins.
Income Statement
38NegativeBalance Sheet
32NegativeCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.58M | 75.92M | 41.51M | 755.00K | 19.17M | 73.95M |
| Gross Profit | 42.25M | 55.04M | 41.51M | 18.00K | 17.40M | 37.67M |
| EBITDA | -43.63M | -21.12M | -9.46M | -92.64M | -76.38M | -78.42M |
| Net Income | -65.27M | -70.35M | -36.76M | -101.06M | -98.69M | -86.28M |
Balance Sheet | ||||||
| Total Assets | 267.37M | 324.72M | 383.54M | 334.27M | 261.22M | 382.08M |
| Cash, Cash Equivalents and Short-Term Investments | 166.85M | 208.66M | 260.31M | 203.81M | 97.70M | 186.13M |
| Total Debt | 84.57M | 90.73M | 91.46M | 85.06M | 82.85M | 102.24M |
| Total Liabilities | 226.30M | 248.85M | 252.51M | 249.57M | 135.28M | 145.60M |
| Stockholders Equity | 41.07M | 75.91M | 131.03M | 84.69M | 117.97M | 221.29M |
Cash Flow | ||||||
| Free Cash Flow | -43.86M | -44.10M | 19.15M | -25.82M | -89.89M | -124.31M |
| Operating Cash Flow | -41.69M | -41.64M | 22.99M | -24.75M | -87.44M | -104.56M |
| Investing Cash Flow | 33.13M | -30.69M | -102.81M | -15.51M | -2.76M | 7.28M |
| Financing Cash Flow | -16.31M | -16.81M | 89.11M | 82.86M | 1.15M | 47.52M |
Cellectis SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 1.06 is above the 20-day moving average (MA) of 1.04, below the 50-day MA of 1.31, and below the 200-day MA of 2.56, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 67.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksCellectis SA Peers Comparison
Overall Rating
FR:IPH48Neutral
FR:TNG48Neutral
FR:NANO47Neutral
FR:ALCLS42Neutral
FR:MAAT38Underperform
FR:OSE38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | EUR 134.04M | -2.35 | 152.56% | ― | -29.48% | 7.91% | |
| 48Neutral | EUR 200.64M | -4.31 | -29.36% | ― | 189.81% | 38.50% | |
| 47Neutral | EUR 1.42B | -25.36 | 89.71% | ― | ― | ― | |
| 42Neutral | EUR 76.38M | -1.78 | -94.14% | ― | -5.98% | -8.67% | |
| 38Underperform | EUR 19.38M | -0.54 | ― | ― | -19.02% | 10.39% | |
| 38Underperform | EUR 40.77M | -1.02 | -96.73% | ― | -96.25% | -197.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALCLS | Cellectis SA | 1.06 | -2.64 | -71.42% | |
| FR:IPH | Innate Pharma S.A. | 1.20 | -0.37 | -23.37% | |
| FR:NANO | Nanobiotix SA | 27.90 | 8.34 | 42.64% | |
| FR:TNG | Transgene SA | 0.72 | -0.58 | -44.75% | |
| FR:OSE | OSE Immunotherapeutics | 1.73 | -3.97 | -69.60% | |
| FR:MAAT | MaaT Pharma | 1.03 | -3.46 | -77.10% |
Cellectis SA Corporate Events
Cellectis Showcases Promising One-Time Gene Editing Approach for Severe Hypertriglyceridemia
Cellectis has unveiled expanded preclinical data for .HEAL-101, an in vivo TALE base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress in Hamburg. The therapy uses liver-direc...
Cellectis Updates Share Capital and Voting Rights as of September 30, 2026
Cellectis reported that as of September 30, 2026, its share capital comprised 100,732,781 shares, corresponding to 105,563,044 voting rights, confirming its current capital and governance structure to the market. The updated share and voting rights d...
Cellectis pivots to in vivo gene editing and exits key CAR-T programs
Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two lead programs, .HEAL-101 and .HEAL-201, targeting severe hypertriglyceridemia and hypercholesterolemia with first Phase 1 data expected in China in 2027 and 2028...
Cellectis Plans September 14 Business Update Webcast for Global Investors
Cellectis SA will host an English- and French-language conference call and webcast on September 14, 2026 to provide a business update to investors and other stakeholders. The company plans to make a replay available on its website, underscoring its e...
Cellectis Updates Share Capital and Voting Rights as of August 31, 2026
Cellectis SA reported that as of August 31, 2026, its share capital consisted of 100,718,974 shares, corresponding to 105,568,956 voting rights. The update on capital and voting rights provides investors and market participants with greater transpare...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
